ВОЗМОЖНОСТИ ЛЕЧЕНИЯ ИНВАЗИВНЫХ ФОРМ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
Аннотация
В данной статье рассматриваются возможности лечения инвазивных форм рака молочной железы (РМЖ), успехи которого связаны с системной терапией. В хирургии РМЖ приоритетным является органо-сохраняющее лечение, позволяющее добиться хороших эстетических результатов без увеличения частоты местных рецидивов и без ухудшения отдаленных результатов. При планировании лечения должны учитываться не только распространенность опухолевого процесса, но и биологический подтип РМЖ.
Литература
Dzhemal A, Vineis P, Brej F, Torre L, Forman D. Atlas sovremennoj onkologii. 2nd ed. Atlanta, shtat Dzhordzhija: Amerikanskoe onkologicheskoe obshhestvo; 2014. 136 p.
Nelyubina LA. Rak molochnoj zhelezy: strategii ocenki i snizhenija riska zabolevanija [Breast cancer: risk assessment and risk reduction strategies]. Vestnik Tambovskogo universiteta [Journal Tambov University Reports]. 2014;19(6):1919-1927. (Russian).
Okeanov AE, Moiseev AA, Evmenenko AA, Levin LF; Sukonko OG, editor. 25 let protiv raka. Uspekhi i problem protivorakovoy borby v Belarusi za 1990-2014 gody [25 years contrary cancer. The successes and challenges of cancer control in Belarus for the years 1990-2014]. Minsk: GU RNMB; 2016. 415 p. (Russian).
Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann. Oncol. 2017;28(8):1700-1712. doi:10.1093/annonc/mdx308.
Semiglazov VF. Itogi 15-j Mezhdunarodnoj konferencii po raku molochnoj zhelezy, San-Gallen, 2017. Jeskalacija i dejeskalacija lechenija [Internet]. Available from: ttps://medvestnik.ru/content/medarticles/Itogi-15-i-Mejdunarodnoi-konferencii-po-raku-molochnoi-jelezy- San-Gallen-2017-Eskalaciya-i-deeskalaciya-lecheniya. html. (Russian).
Generali D, Corona SP, Pusztai L, Rouzier R, Allevi G, Aguggini S, Milani M, Strina C, Frati A. Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR. J. Cancer Res. Clin. Oncol. 2018;144(3):601-606. doi: 10.1007/s00432-017-2574-4.
Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M; Society of Surgical Oncology; American Society for Radiation Oncology. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J. Clin. Oncol. 2014;32(14):1507-1515. doi: 10.1200/JCO.2013.53.3935.
De La Cruz L, Moody AM, Tappy EE, Blankenship SA, Hecht EM. Overall Survival, Disease-Free Survival, Local Recurrence, and Nipple-Areolar Recurrence in the Setting of Nipple-Sparing Mastectomy: A Meta-Analysis and Systematic Review. Ann. Surg. Oncol. 2015;22(10):3241-3249. doi: 10.1245/s10434-015-4739-1.
Moskvina LV, Andreeva YY, Ilatovskaia ME, Matsionis AE, Frank GA, Zavalishina LE, Podberezina YL. Sovremennyj podhod k diagnostike i ocenke lechebnogo jeffekta neoadjuvantnoj terapii pri rake molochnoj zhelezy [A modern approach to the diagnosis and evaluation of regression after neoadjuvant therapy in breast cancer patients]. Zlokachestvennye opuholi [Malignant tumours]. 2017;7(1):38-41. doi: 10.18027/2224-5057-2017-1-38-41. (Russian).
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569-575. doi: 10.1001/jama.2011.90.
El Hage Chehade H, Headon H, El Tokhy O, Heeney J, Kasem A, Mokbel K. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. Am. J. Surg. 2016; 212(5):969-981. doi: 10.1016/j.amjsurg.2016.07.018.
Ministerstvo zdravoohranenija Respubliki Belarus. Ob utverzhdenii klinicheskogo protokola «Algoritmy diagnostiki i lechenija zlokachestvennyh novoobrazovanij». Postanovlenie № 60 (jul. 6, 2018) [Internet]. Available from: http://pravo.by/document/?guid=12551&p0=W-21833500p&p1=1. (Russian).
Semiglazov VF, Semiglazov VV, Nikolaev KS, Komyahov AV, Semiglazova TYu, Paltoev RM, Donskikh RV, Tseluyko AI, Artemyeva AS, Bashlyk VO, Miryusupova GF, Dashyan GA. Dejeskalacija i jeskalacija lechenija pacientov s HER2-pozitivnym rakom molochnoj zhelezy [De-escalation and escalation of treatment of patients with HER2-positive breast cancer]. Farmteka. 2017;17(350):8-13. (Russian).
Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M. Adjuvant ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 2015;372(5):436-446. doi: 10.1056/NEJMoa1412379.
Stenina MB, Frolova MA, Kupchan DZ, Tjulandin SA. Izmenenija v neo- i adjuvantnom lechenii raka molochnoj zhelezy za poslednie 5 let [Changes in neoand adjuvant treatment of breast cancer in the last 5 years]. Prakticheskaja onkologija [Practical oncology]. 2017;18(3):256-264. (Russian).
Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J. Clin. Oncol. 2014;32(21):2255-2269. doi: 10.1200/JCO.2013.54.2258.
